Products

EMARKETER delivers leading-edge research to clients in a variety of forms, including full-length reports and data visualizations to equip you with actionable takeaways for better business decisions.
PRO+
New data sets, deeper insights, and flexible data visualizations.
Learn More
Reports
In-depth analysis, benchmarks and shorter spotlights on digital trends.
Learn More
Forecasts
Interactive projections with 10k+ metrics on market trends, & consumer behavior.
Learn More
Charts
Proprietary data and over 3,000 third-party sources about the most important topics.
Learn More
Industry KPIs
Industry benchmarks for the most important KPIs in digital marketing, advertising, retail and ecommerce.
Learn More
Briefings
Client-only email newsletters with analysis and takeaways from the daily news.
Learn More
Analyst Access Program
Exclusive time with the thought leaders who craft our research.
Learn More

About EMARKETER

Our goal is to unlock digital opportunities for our clients with the world’s most trusted forecasts, analysis, and benchmarks. Spanning five core coverage areas and dozens of industries, our research on digital transformation is exhaustive.
Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More
Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More
Advertising & Sponsorship Opportunities
Reach an engaged audience of decision-makers.
Learn More
Events
Browse our upcoming and past events, recent podcasts, and other featured resources.
Learn More
Podcasts
Tune in to EMARKETER's daily, weekly, and monthly podcasts.
Learn More

Pear Therapeutics takes the public leap in a $1.6B SPAC deal

The news: Digital therapeutics (DTx) firm Pear Therapeutics revealed it’s going public in a SPAC deal with Thimble Point Acquisition Corp at an estimated value of $1.6 billion. It expects to have $400 million in net cash once the deal closes.

How we got here: Pear’s news arrives after its $100 million Series D funding in March—cash it said it would use to get its substance abuse, opioid use disorder, and chronic insomnia DTx in more insurers' formularies to widen treatment access.

Why it could succeed: Pear will be one of the few DTx companies that are publicly traded.

  • Pear’s public debut will give it 4x the net cash it received with its Series D round. The cash infusion could help it conduct clinical trials and prove the ROI of its digital therapies to insurers, which should provide more clinical evidence to attract insurer tie-ups (key to getting its tools into patients’ hands).
  • The DTx firm’s announcement could trigger a string of DTx M&As. For instance: We’ve already posited Omada Health could have an IPO on the horizon, especially as it faces pressure from various SPACs and bankers.

What’s next? Some commercial insurers cover DTx, but convincing the CMS to reimburse digital therapies could help companies like Pear reach a far more sizable population.

For context, the CMS doesn’t currently cover most digital therapies under Medicare or Medicaid—but a temporary rule could begin to change this. In early January, the CMS issued a new rule that would automatically provide Medicare coverage for FDA breakthrough devices for a period of four years—but it’s since delayed enforcement of that rule to December 2021. This means DTx companies like Pear (which previously received FDA breakthrough designation status for its opioid use disorder treatment, for instance) will likely receive some Medicare coverage, but there’s no guarantee it’ll be a long-term rule.

Long-term coverage of digital therapies could be mutually beneficial for the CMS and DTx companies.

  • The CMS covers over 80 million individuals under Medicaid alone—nearly double the size of major commercial insurers like United Healthcare, which boasts 45 million global members.
  • And data reveals that CMS programs like Medicaid bear the brunt of costs associated with treating the US’ opioid epidemic—something a DTx like Pear’s could help stave off by improving health outcomes. Pear says its DTx for opioid use disorder, reSET-O, contributed to a 60% reduction in inpatient and emergency department use, for instance.